Exploring nerve damage in adult survivors of childhood leukemia treated with vincristine
Long-term Evaluation of Vincristine-induced Peripheral Neuropathy in Adult Survivors of a Multicenter Prospective Cohort of Childhood and Adolescent Leukemia (LEA Cohort): a Multicenter Cross-sectional Study
This study is looking to see how common and serious nerve damage is in adults who survived childhood leukemia and were treated with vincristine.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 750 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University Hospital, Clermont-Ferrand Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Clermont-Ferrand) |
| Trial ID | NCT05759052 on ClinicalTrials.gov |
What this trial studies
This observational study aims to assess the prevalence and severity of chemotherapy-induced peripheral neuropathy (CIPN) in adult survivors of childhood leukemia who were treated with vincristine. Participants will be recruited from the French childhood cancer survivor study and will complete a self-administered questionnaire that evaluates their experiences with CIPN and related comorbidities such as pain, anxiety, and quality of life. The study will also collect oncological and sociodemographic data to better understand the impact of vincristine on long-term health outcomes.
Who should consider this trial
Good fit: Ideal candidates for this study are adult survivors of childhood leukemia who received vincristine-based chemotherapy and are over 18 years old.
Not a fit: Patients currently undergoing cancer treatment or those with active oncological pathology will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide valuable insights into the long-term effects of vincristine treatment, potentially leading to improved management strategies for CIPN in cancer survivors.
How similar studies have performed: While studies on CIPN exist, this specific focus on adult survivors of childhood leukemia treated with vincristine is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: - adult patient (\> 18-year) who received a vincristine-based chemotherapy for hematological malignancy in childhood Exclusion Criteria: * Secondary cancer (leukemia and/or cancer) * Active oncological pathology * Current cancer treatment * Adults protected
Where this trial is running
Clermont-Ferrand
- CHU Clermont-Ferrand — Clermont-Ferrand, France (Recruiting)
Study contacts
- Principal investigator: David Balayssac — University Hospital, Clermont-Ferrand
- Study coordinator: Lise LACLAUTRE
- Email: promo_interne_drci@chu-clermontferrand.fr
- Phone: +33473754963
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.